Sirtex, a global healthcare business with offices in the United States, Australia, Europe and Asia, announced on Monday that it has successfully performed the first procedure of selective internal radiation therapy using SIR-Spheres Y-90 resin microspheres for a patient with hepatocellular carcinoma in China, effective 28 September 2021.
The company has achieved this milestone with the support of its shareholder China Grand Pharmaceutical and Healthcare Holdings Limited.
Dr Jiahong Dong, a specialist in hepatobiliary pancreatic surgery and liver transplantation, and his team at Boao Super Hospital in the Hainan Province have carried out the procedure.
In November 2020, the National Medical Products Administration (NMPA) of the People's Republic of China accepted the Sirtex new drug application (NDA) of SIR-Spheres Y-90 resin microspheres for the treatment of colorectal cancer liver metastases.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories